Several strategies have been proposed to help manage the adverse events (AEs) that emerged during the BEACON CRC trial which assessed the effect of encorafenib plus cetuximab in patients with BRAF V600E mutant metastatic colorectal cancer (mCRC) who had progressed after one or two prior regimens.
Liposomal irinotecan in combination with 5-fluorouracil (5-FU), leucovorin (LV) and oxaliplatin (OX) (NALIRIFOX regimen) is tolerable and possesses antitumour activity in previously untreated patients with locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC), according to long-term follow-up results of a phase I/II trial presented at WCGC 2020.
The novel combination regimen comprising the immune checkpoint inhibitors (ICIs) durvalumab (anti-PD-L1) and tremelimumab (anti-CTLA-4) showed a favourable safety profile and clinical activity for advanced hepatocellular carcinoma (HCC), according to detailed safety data presented at ESMO GI 2020.
The combination of encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) improves objective response rate (ORR) in patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC) in the first-line setting, according to the ANCHOR CRC* trial presented at ESMO GI 2020.
The novel switch-control tyrosine kinase inhibitor ripretinib delivered a clinically meaningful benefit for patients with gastrointestinal stromal tumours (GISTs) following crossover from placebo, and had a safety profile consistent with that observed in the double-blind phase, according to the results of the crossover analysis of the INVICTUS trial presented at ESMO GI 2020.
Older patients (aged ≥65 years) with unresectable hepatocellular carcinoma (HCC) may derive greater survival benefit with an atezolizumab + bevacizumab combination compared with sorafenib, according to results of a subgroup analysis of the IMbrave150 trial presented at ESMO GI 2020.
A subgroup analysis of Asian patients enrolled in the CheckMate 040* trial presented at ESMO GI 2020 showed that the nivolumab + ipilimumab (NIVO + IPI) combination regimen had an efficacy and safety profile that was similar to that of the overall population.
In patients with advanced hepatocellular carcinoma (HCC), first-line treatment with nivolumab may confer greater overall survival (OS) than sorafenib, according to updated results of the phase III CheckMate 459* study.
Combination immunotherapy with nivolumab (1 mg/kg) and high-dose ipilimumab (3 mg/kg), given every 3 weeks (nivo1+ipi3 Q3W) for four cycles, followed by flat-dose nivolumab (240 mg) maintenance every 2 weeks (Q2W), achieved greater efficacy vs two high-dose nivolumab (3 mg/kg) and ipilimumab (1 mg/kg) regimens (nivo3+ipi1) in patients with advanced hepatocellular carcinoma (HCC) and in Asian patients, in particular, according to a subanalysis of the phase I/II CheckMate 040 trial presented at the virtual World Congress on Gastrointestinal Cancer (WCGC) 2020.
Irinotecan monotherapy may be as effective as an irinotecan-containing doublet therapy for second-line chemotherapy (CT) for individuals with advanced gallbladder cancers (GBCs) who are progressing on first-line CT, the phase II GB SELECT trial has shown.
Diabetes is a key risk factor for heart failure (HF), which is the leading cause of hospitalization in patients with or without diabetes. SGLT-2* inhibitors (SGLT-2is) have been shown to reduce the risk of hospitalization for HF (HHF) regardless of the presence or absence of diabetes.
Invasive fungal infections, particularly those caused by Candida species, are common in hospitalized, immunocompromised, or critically ill patients and are associated with considerable morbidity and mortality.